(Reuters) – Johnson & Johnson (NYSE:) said on Tuesday it will pay $20.4 million to settle claims by two Ohio counties in a lawsuit that accused the drugmaker of contributing to an U.S. opioid addiction epidemic.
The company said in a statement the settlement removes it from a federal trial against multiple manufacturers and distributors scheduled to begin on Oct. 21..
J&J will pay $10 million to Cuyahoga and Summit counties, reimburse $5 million of their legal and other expenses and provide $5.4 million to non-profit organizations that run opioid-related programs in the counties.
On Monday, Mallinckrodt (NYSE:) Plc finalized a $24 million settlement agreement with the same two counties.
Endo International Plc and Allergan (NYSE:) Plc also settled with the two counties in August to avoid going to trial.
Remaining defendants in the Oct. 21 trial include McKesson Corp (NYSE:), AmerisourceBergen (NYSE:), Cardinal Health (NYSE:), Teva Pharmaceutical Industries (NYSE:) Ltd , Walgreens Boots Alliance (NASDAQ:) Inc and Henry Schein Inc (NASDAQ:).
Earlier in the year, an Oklahoma judge ordered Johnson & Johnson to pay $572.1 million to the state for its part in fueling an opioid epidemic by deceptively marketing addictive painkillers.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.